Chronic nodular prurigo is characterized by recalcitrant itch. Patient perspectives on therapeutic goals, satisfaction with therapy and efficacy of therapeutic regimens for this condition are unknown. This questionnaire study examined these issues in 406 patients with chronic nodular prurigo from 15 European dermatological centres. Improvements in itch, skin lesions and sleep were the most important goals. Emollients, topical corticosteroids and antihistamines were the most frequently used treatments, while a minority of patients were prescribed potent medications, such as systemic immunosuppressants and gabapentinoids. Most patients were not satisfied with their previous therapy (56.8%), while 9.8% did not receive any therapy despite having active disease. A substantial number of respondents (28.7%) considered none of the therapeutic options effective. Although chronic nodular prurigo is a severe disease, most patients were not treated with potent systemic drugs, which may contribute to the high levels of dissatisfaction and disbelief in available therapies. Specific guidelines for chronic nodular prurigo and the development of novel therapies are necessary to improve care.

Pereira, M. P., Zeidler, C., Wallengren, J., Halvorsen, J. A., Weisshaar, E., Garcovich, S., Misery, L., Brenaut, E., Şavk, E., Potekaev, N., Lvov, A., Bobko, S., Szepietowski, J. C., Reich, A., Bozek, A., Legat, F. J., Metz, M., Streit, M., Serra-Baldrich, E., Gonçalo, M., Storck, M., Nau, T., Hoffmann, V., Steinke, S., Greiwe, I., Dugas, M., Augustin, M., Ständer, S., Chronic Nodular Prurigo: A European Cross-sectional Study of Patient Perspectives on Therapeutic Goals and Satisfaction, <<ACTA DERMATO-VENEREOLOGICA>>, 2020; 2020 (N/A): N/A-N/A. [doi:10.2340/00015555-3726] [http://hdl.handle.net/10807/168851]

Chronic Nodular Prurigo: A European Cross-sectional Study of Patient Perspectives on Therapeutic Goals and Satisfaction

Garcovich, Simone;
2020

Abstract

Chronic nodular prurigo is characterized by recalcitrant itch. Patient perspectives on therapeutic goals, satisfaction with therapy and efficacy of therapeutic regimens for this condition are unknown. This questionnaire study examined these issues in 406 patients with chronic nodular prurigo from 15 European dermatological centres. Improvements in itch, skin lesions and sleep were the most important goals. Emollients, topical corticosteroids and antihistamines were the most frequently used treatments, while a minority of patients were prescribed potent medications, such as systemic immunosuppressants and gabapentinoids. Most patients were not satisfied with their previous therapy (56.8%), while 9.8% did not receive any therapy despite having active disease. A substantial number of respondents (28.7%) considered none of the therapeutic options effective. Although chronic nodular prurigo is a severe disease, most patients were not treated with potent systemic drugs, which may contribute to the high levels of dissatisfaction and disbelief in available therapies. Specific guidelines for chronic nodular prurigo and the development of novel therapies are necessary to improve care.
2020
Inglese
Pereira, M. P., Zeidler, C., Wallengren, J., Halvorsen, J. A., Weisshaar, E., Garcovich, S., Misery, L., Brenaut, E., Şavk, E., Potekaev, N., Lvov, A., Bobko, S., Szepietowski, J. C., Reich, A., Bozek, A., Legat, F. J., Metz, M., Streit, M., Serra-Baldrich, E., Gonçalo, M., Storck, M., Nau, T., Hoffmann, V., Steinke, S., Greiwe, I., Dugas, M., Augustin, M., Ständer, S., Chronic Nodular Prurigo: A European Cross-sectional Study of Patient Perspectives on Therapeutic Goals and Satisfaction, <<ACTA DERMATO-VENEREOLOGICA>>, 2020; 2020 (N/A): N/A-N/A. [doi:10.2340/00015555-3726] [http://hdl.handle.net/10807/168851]
File in questo prodotto:
File Dimensione Formato  
5972(1).pdf

accesso aperto

Tipologia file ?: Versione Editoriale (PDF)
Licenza: Creative commons
Dimensione 747.56 kB
Formato Adobe PDF
747.56 kB Adobe PDF Visualizza/Apri

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/10807/168851
Citazioni
  • ???jsp.display-item.citation.pmc??? 2
  • Scopus 24
  • ???jsp.display-item.citation.isi??? 22
social impact